STX2171, a 17 beta-hydroxysteroid dehydrogenase type 3 (17 beta-HSD3) inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model
Reference:
Day, J. M., Foster, P. A., Tutill, H. J., Hargrave, J. D., Schmidlin, F., Vicker, N., Potter, B. V. L., Reed, M. J. and Purohit, A., 2010. STX2171, a 17 beta-hydroxysteroid dehydrogenase type 3 (17 beta-HSD3) inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model. Endocrine Reviews, 31 (3 Supplement 1).
Related documents:
This repository does not currently have the full-text of this item.You may be able to access a copy if URLs are provided below. (Contact Author)
Official URL:
Details
| Item Type | Articles |
| Creators | Day, J. M., Foster, P. A., Tutill, H. J., Hargrave, J. D., Schmidlin, F., Vicker, N., Potter, B. V. L., Reed, M. J. and Purohit, A. |
| Departments | Faculty of Science > Pharmacy & Pharmacology |
| Refereed | No |
| Status | Published |
| ID Code | 23238 |
| Additional Information | Meeting abstract from 92nd Meeting and Expo of the Endocrine Society (ENDO 2010). 19-22 June 2010. San Diego, CA. Suppl. 1 |
Export
Actions (login required)
| View Item |
